Novartis Marks a New Era for Migraine Patients With the EU Approval of Aimovig, a First-of-its-Kind Treatment Specifically Designed for Migraine Prevention
July 30, 2018
July 30, 2018
BASEL, Switzerland, July 30 -- Novartis issued the following news release:
Novartis announced today that the European Commission (EC) approved Aimovig(R) (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia. It works by blocking a receptor called the calcitonin gene-related pept . . .
Novartis announced today that the European Commission (EC) approved Aimovig(R) (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia. It works by blocking a receptor called the calcitonin gene-related pept . . .